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RePORT
What will be new at the back of the eye in the year 2020? 
Shaheen Shah reports from the World   Ophthalmology Congress
shaheen shah
Clinical Research Fellow, International 
Centre for Eye Health, London School 
of Hygiene & Tropical Medicine, 
Keppel Street, London WC1E 7HT, UK.
The World Ophthalmology Congress 
was held from February 19-24, 2006 
in Brazil. I took the opportunity to 
ask some leading experts how they 
think the diagnosis and management 
of posterior segment conditions 
might be different in the future, 
specifically in the year 2020. What 
follows is a summary of their views, 
which we hope will generate interest 
and lively discussion amongst our 
readers and their colleagues. 
Diabetic retinopathy 
Dr Alexander Brucker, Professor of 
Ophthalmology at the University of 
Pennsylvania and Editor of the journal 
Retina, suggests that by the year 2020, 
decisions about treatment will be based on 
diagnosis using high definition optical 
coherence tomography (OCT) visualisation of 
the retina, in conjunction with fluorescein 
angiography (FA). Although the interpretation 
of the clinical findings may be similar, 
management will be more pharmacologically 
directed. He anticipates change will also be 
effected through alteration of the patient’s 
individual risk factor profile. For proliferative 
disease, the treatment will probably continue 
to be with panretinal laser photocoagulation, 
but the addition of new pharmacologic 
agents (e.g. anti-Vascular Endothelial Growth 
Factor or anti-VEGF) could reduce the 
requirement for this destructive treatment.
According to Dr Alistair Laidlaw, 
Consultant Vitreoretinal Specialist at 
St Thomas’ Hospital, London, UK, the 
prevention of diabetic retinopathy through 
effective screening will take priority. He 
foresees an increased use of non-mydriatic, 
wide-field, low-light systems, which will 
make screening comfortable and effective. 
Management will be through improved 
medical care of diabetes overall, and use of 
newer agents (e.g. protein kinase C inhibitors) 
as well as further developments in non-
destructive laser systems. 
Retinopathy of prematurity 
(ROP)
Dr Rajvardhan Azad, Professor of 
Ophthalmology and Head of Vitreo-Retinal 
and ROP unit at the Dr R.P. Centre for 
Ophthalmic Sciences, New Delhi, predicts 
that by 2020, there will be increased 
awareness of the condition amongst 
ophthalmologists and neonatologists 
through better, easier and more cost-
effective imaging of the retina (e.g. RetCam). 
Cell therapy glossary
Adult stem cells
Undifferentiated cells found in most adult tissues. Adult stem cells can renew 
themselves and differentiate to yield all the specialised cell types of the tissue from 
which they originated. Also referred too as ‘somatic stem cells’. 
Cell-based therapies
Treatment in which stem cells are induced to differentiate into the specific cell type 
required to repair damaged or depleted adult cell populations or tissues.
Cellular therapy
A new way to treat disease and injury. It aims to repair damaged and diseased body-parts 
with healthy new cells provided by stem cell transplants. 
Cones
A type of specialised light-sensitive cells (photoreceptors) in the retina that provide sharp 
central vision and colour vision. See also Rods.
Differentiation
The process whereby an unspecialised early embryonic cell acquires the features of a 
specialised cell, such as a heart, liver, or muscle cell.
embryonic stem cells
Primitive (undifferentiated) cells from the embryo that have the potential to become all 
cell types found in the body (totipotent). Embryonic stem cells (ESCs) are derived from 
four to five day-old embryos. 
Gene therapy
Therapy aimed at counteracting the gene defect by substituting normal gene material at 
the site of the problem. 
Mesenchymal stem cells
Stem cells found primarily in the bone marrow that can transform into bone, cartilage, 
fat, and connective tissue. These cells are also referred to as bone marrow stromal cells.
Multipotent stem cells
Stem cells that can give rise to several other cell types, but those types are limited in 
number. An example of multipotent cells is haematopoietic cells – blood stem cells that 
can develop into several types of blood cells. 
Photoreceptors
Cells that are sensitive to light. 
Plasticity
The ability of stem cells from one adult tissue to generate the differentiated cell type of 
another.
Progenitor cells
Cells that can produce only one cell. They can differentiate into a limited number of cell 
types, but cannot make more stem cells (or renew themselves). 
Proliferation
Expansion of a population of cells by the continuous division of single cells.
Regenerative medicine
A treatment in which stem cells are induced to differentiate into the specific cell type 
required to repair damaged or depleted adult cell populations or tissues. 
Retina
The light-sensitive layer of tissue that lines the back of the eyeball; sends visual 
messages through the optic nerve to the brain. 
Retinal pigment epithelium
The pigment cell layer that nourishes the retinal cells; located just outside the retina and 
attached to the choroid. 
Rods
A type of specialised light-sensitive cells (photoreceptors) in the retina that provide side 
vision and the ability to see objects in dim light (night vision). Also see Cones. 
stem cells
Unspecialised cells that serve as the source, or ‘stem’, for specialised cells like heart, 
brain, or blood cells. They have two important characteristics that distinguish them from 
other cells in the body. Firstly, they can replenish their numbers for long periods through 
cell division. Secondly, after receiving certain chemical signals, they can differentiate, or 
transform into specialised cells with specific functions, such as a heart cell or nerve cell. 
Found in days-old embryos and a few adult organs.
subfoveal
Beneath the fovea, the central pit in the macula that produces the sharpest vision. 
undifferentiated cells
Cells that have not changed to become a specialised type of cell. 
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These imaging systems will also improve 
diagnosis and therefore subsequent 
management. Therapies will include 
increased use of angiostatic agents, and 
more focal, less destructive laser treatments. 
The current belief that surgical techniques do 
not work will change as advances in 
techniques develop (e.g. use of plasminogen 
to liquefy the vitreous to reduce the traction). 
Dr Clare Gilbert, Reader in International 
Eye Health at the London School of Hygiene 
and Tropical Medicine, believes that clinical 
trials currently underway (e.g. optimum 
oxygen concentrations for premature babies) 
will help to reduce the incidence of sight-
threatening disease. Until now, detection of 
ROP has been performed by ophthalmolo-
gists using indirect ophthalmoscopy, but in 
the future digital imagery (taken by non-
ophthalmologists) with automated image 
analysis, or remote (telemedicine) expert 
reading, will offer the possibility of screening 
in the true sense of the word. Regarding 
management, she believes that, as with other 
vasoproliferative eye conditions, there will be 
medical treatments that block the disease 
from progressing. The current use of ablation 
techniques will be kept to a minimum. 
Retinoblastoma 
Dr Carol Shields, Professor of Ophthalmology 
and Co-Director of the Oncology Service at 
the Wills Eye Hospital, Philadelphia, foresees 
earlier detection of cases through increased 
awareness (e.g routine screening of the red 
reflex) which will potentially identify the 
sporadic cases. A change in chemotherapy 
treatment from systemic to local delivery will 
reduce overall side-effects. New develop-
ments in slow-release mechanisms (e.g. a 
reservoir system inserted into the sub-Tenon 
space which can then be regularly filled with 
chemotherapeutic agent) and increased use 
of adjunctive treatments (e.g locally placed 
anti-proliferative agents like combret-
astatin), will further improve treatment 
success. 
Dr Alejandra A. Valenzuela of the Royal 
Children’s Hospital, University of Queensland, 
Australia, considers that by 2020, better 
education and increased surveillance by the 
health community will be fundamental to 
earlier diagnosis and sucessful outcomes. 
Multimodal therapeutic advances will save 
not only the life of the patient, but also 
preserve the eye and, in some cases, 
preserve the vision. The addition of gene 
therapy to the particular Rb1 mutation 
affecting some children may provide a further 
avenue in management. 
Retinal detachments 
Dr Yasuo Tano, Professor of Ophthalmology, 
University of Osaka, President of Asia-
Pacific Academy of Ophthalmology, 
envisages that pars plana vitrectomy (PPV) 
will take over as the primary choice for 
detachment repair. Improved imaging with 
3-dimensional OCT high resolution imaging 
will improve visualisation of the posterior 
segment. Non-vitrectomising macular 
surgery may offer the hope of non-accel-
erated progression of nuclear cataract that 
currently occurs following PPV. Bimanual 
techniques for surgery are also likely to be 
more widespread.
Dr G W Aylward, Medical Director at 
Moorfields Eye Hospital, London, foresees 
no significant change in the diagnostic and 
management techniques for routine retinal 
detachments, as reattachment rates 
currently reach 90 per cent. He suggests 
that the main thrust by the year 2020 will be 
focused at the public health level, such as 
alerting the public to early symptoms and 
signs in order to ‘catch’ detachments before 
the macula is affected. 
Dr Borja Corcostegui, President of 
Española de Retina y Vítreo (SERV) and 
Director of Instituto de Microcirugía Ocular 
(IMO), Barcelona, added that, as the 
posterior segment diseases are better 
understood (particularly the vascular 
disorders), the range of conditions that 
require surgery and indications for inter-
vention would be quite different in 2020. 
Age-related macular 
degeneration (AMD)
Dr. Rosario Brancato, Professor of 
Ophthalmology, University San Raffaele, 
Milan, Italy and Editor of the European Journal 
of Ophthalmology, predicts that diagnosis for 
AMD will be directed at three levels: 
• Understanding pathological angiogenic 
mechanisms
• Understanding these effects in the local 
tissue
• Epidemiological and genetic research 
regarding predispositions to AMD.
FA, Indocyanine Green (ICG) angiography and 
OCT will continue to prove useful for diagnosis 
and monitoring evolution of the disease.
Treatments will be directed by the 
diagnosis and will specifically target the 
pathogenic mechanisms. In this regard, 
finding an effective drug for the prevention 
and the regression of pathological neovas-
cularisation will be important. Research and 
development into regenerative therapies will 
also increase in importance. An important 
challenge will also be to identify the best 
delivery systems for these medications (e.g. 
oral, subconjunctival, even topical). 
Retinal dystrophies, 
e.g. retinitis pigmentosa
Dr Ian Constable, Professor of 
Ophthalmology, University of Western 
Australia and Director of Lions Eye Institute, 
Perth, believes that by the year 2020, the 
range of specific gene defects will have 
been documented for the various clinical 
phenotypes. Gene function (e.g. enzymatic, 
cell signaling) for most dystrophies will also 
be understood, and animal models in place. 
Gene therapies will predominantly be 
available for large families or populations, 
however there will be some scope for devel-
oping customised treatments. In general, 
the strategy will be:
• Autosomal recessive – replace the defunct 
gene
•Autosomal dominant – insert a separate 
gene.
Dr Richard Gisbert, Professor of 
Ophthalmology, University of Hamburg and 
co-founder of the European Society of Retinal 
Specialists (EURETINA), foresees  potential 
treatment options for retinal dystrophies in 
the future to include cell replacement strat-
egies (i.e. transplantation of stem cells, 
progenitor cells, primary retinal cells or retinal 
tissue), gene therapy, and, for advanced 
cases, electronic retinal prostheses.
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